SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that applies a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from severe rare diseases and cancer. We are a “start-up with a head start,” having launched in 2017 with a portfolio of clinically validated therapies in-licensed from Pfizer that are now in late-stage clinical trials.
SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates. Our lead pipeline programs are in potentially registrational clinical trials for rare oncology indications: nirogacestat (gamma secretase inhibitor) is in a Phase 3 clinical trial for the treatment of desmoid tumors, and mirdametinib (MEK inhibitor) is in a Phase 2b clinical trial for the treatment of neurofibromatosis type 1 patients with plexiform neurofibromas (NF1-PN). There are currently no therapies approved for either of these devastating tumor types. SpringWorks is also advancing several other programs addressing highly prevalent, genetically defined cancers.
SpringWorks is actively pursuing new licensing and partnership opportunities with industry leaders. We pioneer efficient pathways for drug development, leveraging shared-value partnerships with patient advocacy groups, innovators in industry and academia, and investors so that together, we can unlock the potential of science and bring new therapies to underserved patients.
We are led by an experienced management team with deep expertise in drug development and commercialization. Our team of SpringWorkers is focused on exceptional execution and is driven to deliver life-changing medicines for the patients who are counting on us. At SpringWorks, we ignite the power of promising science to unleash new possibilities for patients.